ACADIA PHARMACEUTICALS INC's ticker is ACAD and the CUSIP is 004225108. A total of 247 filers reported holding ACADIA PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 1.36 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $120 | -14.9% | 5,781 | -1.5% | 0.01% | -16.7% |
| Q2 2023 | $141 | +27.0% | 5,869 | -0.5% | 0.01% | +20.0% |
| Q1 2023 | $111 | +18.1% | 5,901 | -0.3% | 0.01% | +25.0% |
| Q4 2022 | $94 | -99.9% | 5,921 | -16.3% | 0.00% | -20.0% |
| Q3 2022 | $116,000 | -7.9% | 7,073 | -21.1% | 0.01% | +25.0% |
| Q2 2022 | $126,000 | +20.0% | 8,959 | +107.1% | 0.00% | +100.0% |
| Q1 2022 | $105,000 | -9.5% | 4,326 | -13.1% | 0.00% | 0.0% |
| Q4 2021 | $116,000 | +38.1% | 4,979 | -1.6% | 0.00% | 0.0% |
| Q3 2021 | $84,000 | -34.4% | 5,061 | -3.8% | 0.00% | 0.0% |
| Q2 2021 | $128,000 | -5.9% | 5,261 | 0.0% | 0.00% | -33.3% |
| Q1 2021 | $136,000 | -76.0% | 5,261 | -50.3% | 0.00% | -75.0% |
| Q4 2020 | $566,000 | +4.2% | 10,583 | -19.7% | 0.01% | -7.7% |
| Q3 2020 | $543,000 | -15.0% | 13,174 | 0.0% | 0.01% | -18.8% |
| Q2 2020 | $639,000 | +13.5% | 13,174 | -1.1% | 0.02% | 0.0% |
| Q1 2020 | $563,000 | -2.8% | 13,322 | -1.5% | 0.02% | +33.3% |
| Q4 2019 | $579,000 | +16.5% | 13,525 | -2.1% | 0.01% | +9.1% |
| Q3 2019 | $497,000 | +33.2% | 13,821 | -0.9% | 0.01% | +37.5% |
| Q2 2019 | $373,000 | -2.6% | 13,940 | -2.2% | 0.01% | 0.0% |
| Q1 2019 | $383,000 | +65.8% | 14,259 | 0.0% | 0.01% | +33.3% |
| Q4 2018 | $231,000 | -28.0% | 14,259 | -7.8% | 0.01% | 0.0% |
| Q3 2018 | $321,000 | +36.0% | 15,459 | 0.0% | 0.01% | +20.0% |
| Q2 2018 | $236,000 | -35.7% | 15,459 | -5.3% | 0.01% | -28.6% |
| Q1 2018 | $367,000 | -25.4% | 16,332 | 0.0% | 0.01% | -30.0% |
| Q4 2017 | $492,000 | +51.9% | 16,332 | +40.5% | 0.01% | +42.9% |
| Q2 2017 | $324,000 | -19.0% | 11,622 | 0.0% | 0.01% | -22.2% |
| Q1 2017 | $400,000 | -16.5% | 11,622 | -30.0% | 0.01% | -18.2% |
| Q4 2016 | $479,000 | -55.2% | 16,610 | -50.6% | 0.01% | -50.0% |
| Q3 2016 | $1,070,000 | – | 33,644 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Finepoint Capital LP | 556,553 | $11,598,565 | 5.78% |
| Baker Brothers Advisors | 42,864,612 | $893,298,514 | 5.15% |
| RTW INVESTMENTS, LP | 11,576,537 | $241,255,031 | 5.09% |
| Palo Alto Investors LP | 2,405,793 | $50,136,726 | 4.74% |
| Birchview Capital, LP | 240,400 | $5,009,936 | 4.26% |
| EcoR1 Capital, LLC | 5,991,479 | $124,862,422 | 4.21% |
| EMERALD ADVISERS, LLC | 1,681,052 | $35,033,124 | 1.70% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 1,303,988 | $27,175,110 | 1.64% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 179,702 | $3,739,599 | 1.26% |
| SECTOR GAMMA AS | 179,785 | $3,746,719 | 0.96% |